Progressive Multifocal Leukoencephalopathy: Current Insights

Marge Kartau, Jussi O. T. Sipilä, Eeva Auvinen, Maarit Palomäki, Auli Verkkoniemi-Ahola

Tutkimustuotos: ArtikkelijulkaisuKatsausartikkelivertaisarvioitu

Abstrakti

Cases of PML should be evaluated according to predisposing factors, as these subgroups differ by incidence rate, clinical course, and prognosis. The three most significant groups at risk of PML are patients with hematological malignancies mostly previously treated with immunotherapies but also untreated, patients with HIV infection, and patients using monoclonal antibody (mAb) treatments. Epidemiological data is scarce and partly conflicting, but the distribution of the subgroups appears to have changed. While there is no specific anti-JCPyV treatment, restoration of the immune function is the most effective approach to PML treatment. Research is warranted to determine whether immune checkpoint inhibitors could benefit certain PML subgroups. There are no systematic national or international records of PML diagnoses or a risk stratification algorithm, except for MS patients receiving natalizumab (NTZ). These are needed to improve PML risk assessment and to tailor better prevention strategies.

Alkuperäiskielienglanti
LehtiNeurodegenerative Diseases
Vuosikerta9
Sivut109-121
Sivumäärä13
ISSN1660-2854
DOI - pysyväislinkit
TilaJulkaistu - 2 jouluk. 2019
OKM-julkaisutyyppiA2 Katsausartikkeli tieteellisessä aikakauslehdessä

Tieteenalat

  • 3124 Neurologia ja psykiatria

Siteeraa tätä